http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
치매 치료 보조제로서 커큐민의 유효성 및 안전성에 대한 문헌고찰
최선경(Sun Kyung Choi),유봉규(Bong Kyu Yoo) 대한약학회 2020 약학회지 Vol.64 No.5
Curcumin is a polyphenol compound derived from Curcuma longa and possesses potential for alternative option in the management of Alzheimer’s disease. In this literature review, we aimed to evaluate results reported in clinical studies, particularly focusing on efficacy and safety of curcumin in the management of Alzheimer’s disease. A total of 806 articles were searched in the Pubmed and clinicaltrials.gov databases. Four records of the articles were clinically related with Alzheimer’s disease: two phase 1 studies, two phase 2 studies, and all of which being randomized placebo-controlled prospective studies. In phase 1 studies with elderly population having no memory or cognition impairment, curcumin showed beneficial effect on mood and cognition. However, in phase 2 studies with Alzheimer’s disease patients having memory and cognition loss, curcumin failed to show benefits. The inconsistent results might be probably because of short study duration as well as quality differences of curcumin products used in clinical studies. In conclusion, although curcumin might be an alternative option in the prevention of the Alzheimer’s disease, further research is warranted to match in-vitro results with clinical outcomes.
연구논문(硏究論文)(재록(再錄)) : 생명과학 ; β-cyclodextrin의 포접에 의한 난용성 약물인 클로트리마졸의 생체이용을 증가
프라바가 ( Balakrishnan Prbagar ),유봉규 ( Bong Kyu Yoo ),우종수 ( Jong Soo Woo ),김정애 ( Jung Ae Kim ),이종달 ( Jong Dal Rhee ),박명관 ( Ming Guan Piao ),최한곤 ( Han Gon Choi ),용철순 ( Chul Soon Yong ) 영남대학교 약품개발연구소 2007 영남대학교 약품개발연구소 연구업적집 Vol.17 No.-
강민구,강민정,지은희,유봉규,Kang, Min Gu,Kang, Min Jung,Ji, Eunhee,Yoo, Bong Kyu Korean College Of Clinical Pharmacy 2017 한국임상약학회지 Vol.27 No.3
Background: Recently, a fixed combination of grazoprevir and elbasvir (GE) has been introduced to the arsenal of chemotherapeutics to fight against this virus. The study aimed to provide information on the efficacy and safety of GE for the treatment of HCV infection by performing a meta-analysis of literature data. Methods: PubMed and EMBASE database searches were conducted. Among the literature retrieved, pivotal Phase III clinical studies were analyzed. Statistical analysis of the data was performed by RevMan. Results: Four pivotal Phase III clinical studies compared the efficacy and safety of GE. When HCV patients were treated with GE for 12 weeks, the sustained virologic response, defined as the viral RNA level below the lower limit of quantification at 12 weeks after the cessation of therapy (SVR12), was 94.7%. The clinical advantage of GE involves its use by patients with cirrhosis and/or renal failure without dose adjustment. If the genotype (GT) of the causative virus was GT1a with NS5A polymorphism or GT4 with resistance to peginterferon/ribavirin, treatment with GE plus ribavirin for 16 weeks resulted in a better outcome compared to treatment with GE alone for 12 weeks. Adverse events reported during the four clinical studies were 71.09% in the GE arms and it was 76.61% in the non-GE arms, with the most frequent events being mild central nervous system symptoms. Conclusion: GE was generally safe and effective for the treatment of HCV infection. However, since HCV mutates very rapidly and becomes resistant to antiviral agents, long-term monitoring should be mandatory.
병원약제부의 약품식별업무와 질의응답업무에 관한 업무분석;한 대학병원의 경우
최지홍,김정애,스리니바산샨무감,용철순,최한곤,유봉규,Choi, Ji-Hong,Kim, Jung-Ae,Shanmugam, Srinivasan,Yong, Chul-Soon,Choi, Han-Gon,Yoo, Bong-Kyu 대한약학회 2008 약학회지 Vol.52 No.4
Drug identification service and other drug-related query service are becoming increasingly important in hospital pharmacy. The goal of this research was to investigate current situation of the service in hospital pharmacy, which recently implemented the services as part of provision of advanced hospital pharmacy service in order to assure national health improvement. We investigated the report performed from November 2006 through April 2007 in a university hospital located in Daegu, Korea. Number of drug identification service performed was 81 cases during the first three months period (period I), but it increased to 222 cases during the second three months period (period II), which suggested that the service was welcomed by medical staff in the hospital. Time to process each case was about 30 minutes in the period I while it was only 16 minutes in the period II. Proportion of the unidentifiable cases remained at about 25% during the entire period, which suggests that the system for the identification task appears to have some limitations such as unsatisfactory support from the Korea Pharmaceutical Association, laws, and regulations. A vast majority of drug-related queries were mostly from physicians (60.5%) followed by nurses and pharmacists. Time to process each drug-related query was 10.6 minutes in the period I while it was 6.9 minutes in the period II. Queries answered immediately were about 70% of all queries in the period I, but increased to about 85% in the period II.
이경희,스리니바산샨무감,렌가라잔바스카란,산토쉬쿠마르나가야스리라만,용철순,최한곤,우종수,유봉규,Lee, Kyung-Hee,Shanmugam, Srinivasan,Baskaran, Rengarajan,Nagayya-Sriraman, Santhoshkumar,Yong, Chul-Soon,Choi, Han-Gon,Woo, Jong-Soo,Yoo, Bong-Kyu 대한약학회 2008 약학회지 Vol.52 No.4
Olanzapine, an atypical antipsychotic, has been widely used for the treatment of schizophrenia and bipolar disease. Although olanzapine is less associated with extrapyramidal symptoms and neuroleptic malignant syndrome compared to existing typical antipsychotics, the use of this drug has a problematic side effect of weight gain, which may cause metabolic syndrome such as type 2 diabetes. However, there are few hospitals practicing body weight monitoring of the patients on olanzapine or other atypical antipsychotics. The goal of this study was to identify the incidence and severity of weight gain associated with the use of the drug in Korea. We performed body weight monitoring of the patients who were on the drug in a hospital setting. Mean of the weight gain (as of one-month-transformation) was 4.33 and 3.39 kg for the male and female patients, respectively. The incidence in the young patients was higher than that observed in the old patients, and the severity was the highest in patients in their thirties followed by twenties or younger. This result suggests that the pattern of the weight gain associated with the use of olanzapine in Korea is similar to the reports performed and documented in US and European countries. Therefore, it appears that healthcare professionals in Korea should also watch on the weight gain issue in patients who are on olanzapine or other atypical antipsychotics.